Francisco Torrens | Pharmacology | Breakthrough Research Award

Breakthrough Research Award

             Francisco Torrens
Affiliation Universitat de València
Country Spain
Scopus ID 56924529100
Documents 255
Citations 4,190
h-index 33
Subject Area Pharmacology
Event International Research Awards
ORCID 0000-0003-1737-2321

Francisco Torrens

Universitat de València, Spain

Francisco Torrens is a researcher affiliated with Universitat de València whose scholarly activities have contributed to pharmacology and related interdisciplinary scientific fields. His publication record, citation performance, and internationally indexed research profile demonstrate sustained academic engagement and measurable scientific influence. These achievements support recognition within competitive research award programs and international scholarly evaluations.[1]

Abstract

Francisco Torrens has established a distinguished academic profile through sustained research activity, international publications, and measurable scientific influence within pharmacology and interdisciplinary computational sciences. His Scopus-indexed record includes 255 publications, more than 4,190 citations, and an h-index of 33, reflecting consistent scholarly productivity and broad research visibility. His work has supported scientific understanding through theoretical investigations, collaborative studies, and methodological developments that contribute to international research communities. These achievements demonstrate academic excellence, research continuity, and global scholarly recognition, making his profile well aligned with the objectives and evaluation standards of the Breakthrough Research Award.[1][2]

Keywords

Pharmacology, Computational Chemistry, Molecular Modeling, Drug Discovery, Scientific Research, Scopus Author, Citation Impact, International Research Awards, Breakthrough Research Award, Research Excellence.

Introduction

Scientific recognition is founded upon sustained research productivity, scholarly quality, and measurable academic influence. Francisco Torrens has developed an established research career supported by extensive publications, international collaborations, and consistent citation performance that reflects the relevance of his scientific contributions within pharmacology and computational research disciplines.[1]

Research Profile

Based at Universitat de València, Francisco Torrens has maintained an internationally visible academic profile indexed by Scopus and ORCID. His publication metrics demonstrate long-term scholarly engagement while supporting interdisciplinary research activities across pharmacology, computational chemistry, molecular science, and related analytical methodologies.[1]

Research Contributions

His research contributions emphasize theoretical investigations, computational approaches, molecular characterization, and scientific modeling that enhance understanding of biologically relevant systems. Through peer-reviewed publications and collaborative research, he has contributed valuable knowledge supporting evidence-based scientific advancement across multiple research domains.[2]

Publications

Francisco Torrens has authored or co-authored 255 Scopus-indexed publications that collectively demonstrate consistent scholarly productivity. His publications have appeared in internationally recognized scientific journals, contributing to ongoing developments in pharmacology, computational chemistry, molecular science, and interdisciplinary biomedical research.[1]

Research Impact

With more than 4,190 citations and an h-index of 33, his research demonstrates sustained academic influence across international scientific literature. These bibliometric indicators illustrate the continued relevance, visibility, and utilization of his published work within the global research community.[3]

Award Suitability

The Breakthrough Research Award recognizes researchers demonstrating significant scholarly achievement, measurable scientific impact, and continued research excellence. Francisco Torrens satisfies these evaluation criteria through his publication record, citation performance, interdisciplinary collaborations, and internationally recognized academic profile.[4]

Conclusion

Francisco Torrens represents an accomplished researcher whose scholarly record reflects sustained productivity, scientific influence, and international visibility. His research achievements, recognized publication metrics, and established academic profile support his suitability for consideration within the International Research Awards and similar programs recognizing research excellence.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Francisco Torrens. Author ID 56924529100. Scopus.
    https://www.scopus.com/pages/authors/56924529100
  2. ORCID. (n.d.). ORCID author details: Francisco Torrens.
    https://orcid.org/0000-0003-1737-2321
  3. International Research Awards. (n.d.). Breakthrough Research Award.
    https://researchawards.net/
  4. Sandoval-Vásquez, C., Cárcamo, I., Lagos, P., Muñoz, A., Zavala, F., Colil, V., Villagrán-Silva, F., Vásquez-Carrasco, E., Hernandez-Martinez, J., Valdés-Badilla, P., Torrens, F., Fincheira, P., & Sepúlveda, P. (2025). Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: A systematic review. Frontiers in Pharmacology, 16, 1710176.
    https://doi.org/10.3389/fphar.2025.1710176
  5. Canizares-Carmenate, Y., Perez-Gimenez, F., Diaz-Amador, R., Torrens, F., & Castillo-Garit, J. A. (2025). Discovery of diphenylsilane compounds as potential inhibitors of Zn-metalloproteinase thermolysin using artificial neural networks. Current Computer-Aided Drug Design. Advance online publication.
    https://doi.org/10.2174/0115680266369656250428053942

Mohamed Taha | Neuroscience | Research Excellence Award

Dr. Mohamed Taha | Neuroscience | Research Excellence Award 

Massachusetts General Hospital | United States

Dr. Mohamed Adel Osman Taha is an accomplished physician-scientist whose work bridges clinical neurology, neuromuscular medicine, and advanced applications of artificial intelligence in neurological diagnostics. His academic and clinical training spans leading global institutions, including fellowships in Advanced General & Autoimmune Neurology at Massachusetts General Hospital, Neuromuscular Medicine at the Cleveland Clinic Foundation, and Neurohospitalist Medicine at Stanford University. He also holds advanced master’s degrees in Stem Cells and Translational Neurology from the University of Edinburgh and in Genomic Medicine from the University of Manchester, reflecting a deep interdisciplinary foundation in neuroscience, genetics, and regenerative neurology. Dr. Taha’s research focuses on leveraging digital health technologies, AI-driven diagnostic tools, and advanced neurophysiology to improve the detection, characterization, and management of neuromuscular and neurodegenerative disorders. His scholarly contributions include impactful studies on electromyography signal classification using artificial intelligence, the clinical reliability of ICD-10 coding for stroke severity, and the role of AI in electrodiagnostic medicine—work published in high-impact journals such as Muscle & Nerve, BMJ Neurology Open, and npj Digital Medicine. These efforts underscore his commitment to translating computational innovations into precise, scalable clinical tools. His published research encompasses artificial intelligence in EMG and seizure detection, digital biomarkers, genotype–phenotype correlations, stroke outcome evaluation, and the interactions between neurologic therapeutics and anticoagulants. Dr. Taha has also contributed to the understanding of rare neurological diseases, leukoencephalopathies, and epilepsy-related challenges through case reports, systematic reviews, and population-based studies. His contributions extend to multi-institutional collaborations, including establishing neurocritical EEG databases and developing deep learning models for neuromuscular disease assessment. He has authored book chapters, research protocols, peer-reviewed abstracts, and numerous conference presentations at major neurological scientific meetings, including the American Academy of Neurology, the American Epilepsy Society, and the American Association of Neuromuscular & Electrodiagnostic Medicine. His book chapter on digital health in neurology further highlights his forward-looking approach to integrating technology with clinical practice. Beyond research, Dr. Taha has contributed significantly to academic medicine through resident education, cross-continental neurology outreach initiatives, and the founding of research groups aimed at strengthening scientific capacity in underserved regions. His growing body of work reflects a strong commitment to innovation, interdisciplinary collaboration, and improving neurological care through data-driven, technology-enhanced solutions.

Profile: Google Scholar

Featured Publications

Elamin, E. M., Guizani, I., Guerbouj, S., Gramiccia, M., El Hassan, A. M., & others. (2008). Identification of Leishmania donovani as a cause of cutaneous leishmaniasis in Sudan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102(1), 75–80.

Taha, M. A., & Morren, J. A. (2024). The role of artificial intelligence in electrodiagnostic and neuromuscular medicine: Current state and future directions. Muscle & Nerve, 69(3), 260–272.

Taha, M., Li, W., Schmidt, C. M., Gonzalez-Castellon, M., & Taraschenko, O. (2020). The interactions between anticonvulsants and non-vitamin K antagonist oral anticoagulant agents: A systematic review. Epilepsy Research, 162, 106304.

Saab, K., Tang, S., Taha, M., Lee-Messer, C., Re, C., & Rubin, D. L. (2024). Towards trustworthy seizure onset detection using workflow notes. npj Digital Medicine, 7(1), 42.

Elimam, A. A., Aabdein, M. E. M. M., Eldeen, M. E. F. M., Altayb, H. N., Taha, M. A., & others. (2017). Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer. BMC Medical Genetics, 18(1), 85.

Hamid, O., Taha, M. A. O., Balla, S. A., & Hussien, A. (2013). Stigma of epilepsy among patients and their relatives attending charity clinic, Omdurman—Sudan. Journal of the Neurological Sciences, 333, e61–e62.

Hassan, A., El-Sayed, S., & Taha, M. (2012). Impact of a designed educational program on thyroidectomy patients’ discharge compliance instructions. Journal of American Science, 8(11), 1–3.

Taha, M., Li, Y., Morren, J., & Morren, J. A. (2023). Oxymetazoline hydrochloride eye-drops as treatment for myasthenia gravis-related ptosis: A description of two cases. Cureus, 15(3).